Profile data is unavailable for this security.
About the company
Mega Lifesciences Public Company Limited is a Thailand-based company, which is engaged in health and wellness industry. Its segments include Brands, Distribution and OEM. MEGA We Care is its branded products business, through which it develops, manufactures, markets and sells its own range of nutraceuticals, complementary medicines, prescription pharmaceuticals and over the counter (OTC) health products. Maxxcare serves as its prominent distribution arm, specializing in the marketing, sales, and distribution of a range of branded prescription pharmaceuticals, OTC medications and fast-moving consumer goods (FMCG) across key markets such as Myanmar, Vietnam and Cambodia. Its suite of services encompasses warehouse management, collections and value-added initiatives, including tailored marketing services for principals in the pharmaceutical and FMCG sectors. Its manufacturing facilities in Thailand, Australia and Indonesia also accept production orders from various third-party customers.
- Revenue in THB (TTM)14.15bn
- Net income in THB1.91bn
- Incorporated2013
- Employees5.31k
- LocationMega Lifesciences PCLFloor 9 and 10, Ample Tower Building120 Mu 11, Bangna-Trat RoadBangnaBANGKOK 10280ThailandTHA
- Phone+66 27694222
- Fax+66 27694244
- Websitehttps://www.megawecare.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Haixin Group Co Ltd | 3.57bn | 707.52m | 31.77bn | 715.00 | 64.14 | 2.15 | -- | 8.90 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 3.22bn | -283.79m | 31.97bn | 925.00 | -- | 3.98 | -- | 9.92 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Genomma Lab Internacional SAB de CV | 31.62bn | 2.90bn | 32.86bn | 1.47k | 11.12 | 1.60 | 8.76 | 1.04 | 1.64 | 1.64 | 17.90 | 11.38 | 0.7488 | 3.25 | 3.59 | 11,973,490.00 | 6.86 | 6.81 | 9.72 | 10.16 | 62.84 | 62.13 | 9.16 | 8.78 | 1.52 | 2.57 | 0.407 | 43.40 | -5.73 | 4.81 | -23.13 | 2.75 | -4.00 | -- |
| Corona Remedies Ltd | 4.58bn | 584.23m | 33.10bn | 4.57k | 56.66 | -- | 46.46 | 7.22 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
| Mega Lifesciences PCL | 14.15bn | 1.91bn | 33.13bn | 5.31k | 17.34 | 3.24 | 14.60 | 2.34 | 2.19 | 2.19 | 16.22 | 11.72 | 0.9441 | 2.23 | 4.50 | -- | 12.76 | 14.45 | 18.25 | 21.73 | 52.19 | 46.91 | 13.51 | 13.47 | 1.63 | 5.40 | 0.0627 | 54.27 | -7.80 | 2.36 | -4.99 | 6.54 | 21.20 | 12.20 |
| Lushang Freda Pharmaceutical Co Ltd | 17.10bn | 969.51m | 33.97bn | 3.63k | 34.95 | 1.79 | -- | 1.99 | 0.2112 | 0.2112 | 3.72 | 4.12 | 0.633 | 3.37 | 7.63 | 1,040,448.00 | 4.45 | 0.7994 | 6.29 | 5.29 | 51.41 | 23.96 | 7.02 | 3.71 | 3.96 | -- | 0.0393 | 43.21 | -13.02 | -17.29 | -19.73 | -6.70 | 21.16 | 0.00 |
| Day One Biopharmaceuticals Inc | 4.91bn | -3.33bn | 34.00bn | 178.00 | -- | 2.47 | -- | 6.92 | -1.04 | -1.04 | 1.53 | 4.28 | 0.2901 | 3.57 | 7.79 | 888,662.90 | -19.68 | -32.37 | -22.44 | -35.43 | 89.12 | -- | -67.85 | -209.67 | 7.91 | -- | 0.00 | -- | 20.60 | -- | -12.38 | -- | 110.70 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 7.23bn | -1.51bn | 34.17bn | 2.35k | -- | 1.04 | -- | 4.73 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Polypeptide Group AG | 13.59bn | -1.27bn | 34.21bn | 1.37k | -- | 2.81 | -- | 2.52 | -0.9467 | -0.9467 | 10.06 | 9.11 | 0.5153 | 2.06 | 6.35 | 260,628.70 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 23.92m | 2.74% |
| Thai Life Insurance Public Co. Ltd. (Investment Portfolio)as of 10 Mar 2025 | 16.93m | 1.94% |
| Aberdeen Asset Management (Thailand) Co., Ltd.as of 30 Sep 2025 | 14.16m | 1.63% |
| FIL Investment Management (Singapore) Ltd.as of 31 Dec 2025 | 6.34m | 0.73% |
| Lazard Asset Management LLCas of 31 Mar 2025 | 4.97m | 0.57% |
| Krungsri Asset Management Co., Ltd.as of 30 Sep 2025 | 3.55m | 0.41% |
| AllianceBernstein Ltd.as of 31 Dec 2025 | 2.05m | 0.24% |
| TISCO Asset Management Co., Ltd.as of 30 Sep 2025 | 1.86m | 0.21% |
| BBL Asset Management Co., Ltd.as of 30 Sep 2025 | 1.64m | 0.19% |
| SCB Asset Management Co., Ltd.as of 30 Sep 2025 | 1.46m | 0.17% |
